The neovascular age-related macular degeneration database: Report 2: Incidence, management, and visual outcomes of second treated eyes

Ophthalmology

Volumn 121, Issue 10, 2014, Pages 1966-1975

  Zarranz Ventura, Javier ^a   Liew, Gerald ^a   Johnston, Robert L ^a   Xing, Wen ^a   Akerele, Toks ^a   McKibbin, Martin ^a   Downey, Louise ^a   Natha, Salim ^a   Chakravarthy, Usha ^a   Bailey, Clare ^a   Khan, Rehna ^a   Antcliff, Richard ^a   Armstrong, Stewart ^a   Varma, Atul ^a   Kumar, Vineeth ^a   Tsaloumas, Marie ^a   Mandal, Kaveri ^a   Bunce, Catey ^a   Tufail, Adnan ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; AGE; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; VISUAL ACUITY; CLINICAL TRIAL; MIDDLE AGED; RETINA MACULA DEGENERATION; SUBRETINAL NEOVASCULARIZATION; UNITED KINGDOM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; MACULAR DEGENERATION; MALE; MIDDLE AGED; VISUAL ACUITY;

EID: 84908149389     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.04.026     Document Type: Article

References (41)

1. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
2. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
3. National Institute for Health and Care Excellence. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. NICE technology appraisal guidance 155. Last modified May 2012. Available at: http://www.nice.org.uk/nicemedia/live/12057/41719/41719.pdf. Accessed January 20, 2014.
4. CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
5. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group D.F. Martin, M.G. Maguire, and S.L. Fine Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
6. U. Chakravarthy, S.P. Harding, C.A. Rogers IVAN Study Investigators Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 2012 1399 1411
7. U. Chakravarthy, S.P. Harding, C.A. Rogers IVAN Study Investigators Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial Lancet 382 2013 1258 1267
8. O.P. Gupta, G. Shienbaum, and A.H. Patel A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact Ophthalmology 117 2010 2134 2140
9. H. Oubraham, S.Y. Cohen, and S. Samimi Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration Retina 31 2011 26 30
10. T. Bandukwala, R.H. Muni, and C. Schwartz Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review Can J Ophthalmol 45 2010 590 595
11. T. Rotsos, P.J. Patel, F.K. Chen, and A. Tufail Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration Clin Ophthalmol 4 2010 1271 1275
12. H. Dadgostar, A.A. Ventura, and J.Y. Chung Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration Ophthalmology 116 2009 1740 1747
13. T.R. Friberg, R.A. Bilonick, and P.M. Brennen Risk factors for conversion to neovascular age-related macular degeneration based on longitudinal morphologic and visual acuity data Ophthalmology 119 2012 1432 1437
14. T.R. Friberg, R.A. Bilonick, and P. Brennen Is drusen area really so important? An assessment of risk of conversion to neovascular AMD based on computerized measurements of drusen Invest Ophthalmol Vis Sci 53 2012 1742 1751
15. C. Lange, N. Feltgen, and B. Junker Resolving the clinical acuity categories "hand motion" and "counting fingers" using the Freiburg Visual Acuity Test (FrACT) Graefes Arch Clin Exp Ophthalmol 247 2009 137 142
16. N.Z. Gregori, W. Feuer, and P.J. Rosenfeld Novel method for analyzing Snellen visual acuity measurements Retina 30 2010 1046 1050
17. A.H. Ross, P.H. Donachie, and A. Sallam Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab? Eye (Lond) 27 2013 56 64
18. T.A. Williams, and C.P. Blyth Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12 Eye (Lond) 25 2011 1617 1621
19. Writing Committee for the UK Age-related Macular Degeneration EMR Users Group The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections. Report 1: visual acuity Ophthalmology 121 2014 1092 1101
20. J.M. Seddon, P.J. Francis, and S. George Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration JAMA 297 2007 1793 1800
21. M.A. Brantley Jr., A.M. Fang, and J.M. King Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab Ophthalmology 114 2007 2168 2173
22. I.K. Kim, F. Ji, and M.A. Morrison Comprehensive analysis of CRP, CFH Y402H and environmental risk factors on risk of neovascular age-related macular degeneration Mol Vis [serial online] 14 2008 1487 1495 Available at: http://www.molvis.org/molvis/v14/a177/ Accessed January 20, 2014
23. A.S. Pai, P. Mitchell, and E. Rochtchina Complement factor H and the bilaterality of age-related macular degeneration: the Blue Mountains Eye Study Arch Ophthalmol 127 2009 1339 1344
24. B. Kloeckener-Gruissem, D. Barthelmes, and S. Labs Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD Invest Ophthalmol Vis Sci 52 2011 4694 4702
25. D.C. Minassian, A. Reidy, A. Lightstone, and P. Desai Modelling the prevalence of age-related macular degeneration (2010-2020) in the UK: expected impact of anti-vascular endothelial growth factor (VEGF) therapy Br J Ophthalmol 95 2011 1433 1436
26. Age-Related Eye Disease Study Research Group A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 Arch Ophthalmol 119 2001 1417 1436
27. M.G. Maguire, E. Daniel, A.R. Shah Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research Group) Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age-Related Macular Degeneration Treatments Trials Ophthalmology 120 2013 2035 2041
28. D.J. Pieramici, and S.B. Bressler Age-related macular degeneration and risk factors for the development of choroidal neovascularization in the fellow eye Curr Opin Ophthalmol 9 1998 38 46
29. Submacular Surgery Trials Research Group Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age-related macular degeneration: SST report no. 20 from the Submacular Surgery Trials Research Group Arch Ophthalmol 125 2007 1323 1330
30. Macular Photocoagulation Study Group Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration Arch Ophthalmol 115 1997 741 747
31. I.A. Barbazetto, N. Saroj, and H. Shapiro Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials Am J Ophthalmol 149 2010 939 946
32. J.J. Wang, E. Rochtchina, and A.J. Lee Ten-year incidence and progression of age-related maculopathy: the Blue Mountains Eye Study Ophthalmology 114 2007 92 98
33. Age-Related Eye Disease Study Research Group Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS): AREDS report no. 19 Ophthalmology 112 2005 533 539
34. C.I. Sinapis, J.G. Routsias, and A.I. Sinapis Pharmacokinetics of intravitreal bevacizumab (Avastin) in rabbits Clin Ophthalmol 5 2011 697 704
35. S.J. Bakri, M.R. Snyder, and J.M. Reid Pharmacokinetics of intravitreal bevacizumab (Avastin) Ophthalmology 114 2007 855 859
36. S.J. Bakri, M.R. Snyder, and J.M. Reid Pharmacokinetics of intravitreal ranibizumab (Lucentis) Ophthalmology 114 2007 2179 2182
37. C. Bunce, and R. Wormald Causes of blind certifications in England and Wales: April 1999-March 2000 Eye (Lond) 22 2008 905 911
38. C. Bunce, W. Xing, and R. Wormald Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008 Eye (Lond) 24 2010 1692 1699
39. C.G. Owen, A.E. Fletcher, M. Donoghue, and A.R. Rudnicka How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol 87 2003 312 317
40. L. Arias, I. Roman, and C. Masuet-Aumatell One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections Retina 31 2011 1261 1267
41. J.S. Heier, D.M. Brown, and V. Chong VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration Ophthalmology 119 2012 2537 2548